These are my numbers:

- Kit tests: they have guided 8 million $ revenue for the second half of the year, which would be certainly a significant growth comparing it to 2 million $ in Q2. I would divided those 8 million $ (4-5 Q3 and 3-4 Q4). Being conservative Q3 should be 3-5 million $.
- Patches (including lose weight series and anti-smoking patches). I believe that patches division is going to be an important area for the coming quarters, I even would dare to say that anti-smoking patch is going to be their best selling product for the next year, furthermore they consider these products will have great acceptance in global markets. This quarter they will start generating revenue from the recently approved patches but will not reflect the real posibilities of this area that will increase traction in 2009. In a few words Q3 revenue 6-8 million $.
- Ointments: revenue from new products (partly in Q3) and expanding sales marketing should mean increasing revenue. 6-8 million $.
- Rest of products 10-12 million $

Total medium range: 27-31
eps: 0,55-0,60
That is my opinion for the quarter which is quite above market estimates (0,45 eps).
Anyway, they are usually conservative, if they announce guidance they will say more than 5 cents less than their real estimates
For Q4 the range is wider, I expect 0,45-0,55 eps (still higher than yahoo estimates 0,40).
Full year estimates 2008 eps 1,75-2,00.